Business Context and Reporting Period
This Form 8-K is filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) for the reporting period ending July 31, 2020. The filing reports the entry into a material definitive agreement regarding the exchange of previously issued warrants for common stock.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a capital structure transaction.
- Transaction Type: Warrant Exchange Agreement.
- Counterparty: Armistice Capital Master Fund Ltd.
- Shares Issued: 215,000 shares of Common Stock.
- Warrants Surrendered:
- 2018 Warrant: 160,257 shares (post-reverse split basis).
- 2019 Warrant: 208,334 shares (post-reverse split basis).
- Execution Date: August 3, 2020.
Material Changes
The primary material change is the reduction of outstanding warrant obligations in exchange for the issuance of new common stock. This transaction eliminates the Company's obligation to issue approximately 368,591 shares (the sum of the warrant coverage) upon future exercise, replacing it with an immediate issuance of 215,000 shares.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of general business risks. The transaction is executed in reliance on Section 3(a)(9) of the Securities Act of 1933, indicating an exchange of securities without registration.
Investor Verification Checklist
- Verify the exact terms of the Warrant Exchange Agreement filed as Exhibit 10.1.
- Confirm the impact of the 215,000 new shares on total outstanding share count and potential dilution.
- Review the Company's cash position to ensure liquidity is sufficient to support operations post-transaction.
- Check for any subsequent filings regarding the settlement of the August 3, 2020 issuance.